BioSpace News Archive

Biohaven Ltd. today reported financial results for the third quarter ended September 30, 2022, and provided a review of recent accomplishments and anticipated upcoming milestones. .

LENSAR, Inc. today announced financial results for the quarter ended September 30, 2022 and provided a business update.

Silence Therapeutics plc today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present a business overview at the Jefferies London Healthcare Conference on Wednesday, November 16th at 8:00 a.m. GMT.

Enanta Pharmaceuticals, Inc. today announced the initiation of SPRINT(SARS-Cov-2 PRotease INhibitor Treatment), a Phase 2 clinical trial of EDP-235, Enanta’s lead oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19.

Vedanta Biosciences today announced that Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences, will present at the 9th International Human Microbiome Consortium Congress (IHMC), being held from November 8 – 10, 2022.

The Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has voted 16 to 1 that the data support a favorable benefit risk assessment for the use of PT027 (albuterol/budesonide) for the treatment of asthma in people aged 18 years and older.

BridgeBio Pharma, Inc. today announced that members of the management team will participate in the following upcoming investor conferences.

Medivir AB today announces that the poster, titled “Fostrox (MIV-818) in combination with anti-PD-1 shows increased efficacy in nonclinical tumour models in vivo” will be presented at the SITC 2022 conference, on November 10 by Fredrik Öberg, CSO at Medivir.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).

Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16th, at 10:55 AM GMT.